Stai navigando con un browser obsoleto. per favore aggiorna il tuo browser per migliorare la tua esperienza e la tua sicurezza.

CDP Venture Capital
Nova Milanese (MB) Life Science

Aileens Pharma

The company was founded with the aim of providing the the first effective, safe and non-pharmacological treatment, for the main inflammatory skin diseases, in adults and children. LimpiAD is the first medical device of our pipeline based on HA-C40 a biotech mucopolysaccharide compound chemically conjugated to purified bacterial cell walls. Aileens owns patent on the bacterial strain and production method..
Aileens aims to have a disruptive and innovative therapeutic approach, seeing the recent scientific discoveries that shown the fundamental role played by the skin microbiome in the onset of inflammatory skin diseases.

The ecosystem supporting innovation in Italy